查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1992164

DNA診斷市場：按技術、應用、產品類型和最終用戶分類－2026-2032年全球市場預測

DNA Diagnostics Market by Technology, Application, Product Type, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

DNA診斷市場預計到2025年將達到135.9億美元，到2026年將成長到147.7億美元，到2032年將達到257億美元，複合年成長率為9.52%。

主要市場統計數據
基準年 2025 135.9億美元
預計年份：2026年 147.7億美元
預測年份 2032 257億美元
複合年成長率 (%) 9.52%

本書以現代視角介紹了 DNA 診斷生態系統，重點關注科學進步、監管變化和營運壓力等因素如何重塑診斷決策。

本導論整體情況了現代DNA診斷技術，重點在於影響診斷實踐和研究的科學、監管和技術因素的融合。近年來，定序化學和生物資訊流程的進步顯著提升了診斷的處理能力和準確性，同時監管機構也制定了強調分析有效性、臨床效用和上市後監管的框架。同時，檢查室工作流程也不斷調整，以平衡高度複雜的檢測與快速出結果和成本控制之間的平衡。

分子技術的融合、臨床應用的擴展以及數位平台的整合，正在為診斷和護理路徑帶來系統性的變革。

在技​​術成熟和臨床範式不斷演進的推動下，整個DNA診斷生態系統正在經歷一場變革性的轉變。定序平台，特別是與傳統Sanger測序並行使用的次世代定序技術，如今已與聚合酵素鏈鎖反應（PCR）、微陣列技術和螢光雜合反應（FISH）等成熟的分子技術並存，使得檢查室能夠根據處理能力、解析度和臨床背景選擇合適的工具。這些技術選擇會影響從樣本製備到資料解讀的下游工作流程，因此需要同步開發穩健的生物資訊學和品管流程。

評估 2025 年美國關稅調整對診斷產業供應鏈的韌性和採購計畫的營運和策略影響。

美國將於2025年實施新的關稅措施，將進一步增加DNA診斷領域全球供應鏈和籌資策略的複雜性。關稅變化將改變進口設備、試劑和專用耗材的相對成本結構，進而影響採購決策、庫存緩衝以及對本地生產的投資。因此，供應商和檢查室營運商需要重新審視供應商協議，評估替代採購途徑，並考慮對長期供應商關係的影響。

複雜的細分分析揭示了技術、臨床應用、產品陣容和最終用戶需求如何全面決定採用軌跡和投資重點。

關鍵的細分洞察揭示了差異化技術平台、臨床應用、產品系列和終端用戶類型如何影響技術採納路徑和營運模式。在技​​術層面，螢光雜合反應和微陣列等傳統和標靶技術繼續應用於特定的診斷領域，而聚合酵素鏈鎖反應(PCR) 則在快速、高靈敏度檢測方面保持主導地位。包括次世代定序和桑格定序在內的定序方法正分別擴展到全面的基因組分析和確證檢測領域，每種方法都有其獨特的處理和資料處理需求。

美洲、歐洲、中東和非洲以及亞太地區在診斷領域的採用、監管和供應策略方面的影響的比較趨勢。

區域趨勢持續對整個DNA診斷領域的技術應用、監管方式和合作生態系統產生重大影響。在美洲，成熟的臨床網路和完善的報銷機制支持了先進基因組檢測的廣泛應用，但成本壓力和支付方期望的改變促使人們更加關注檢測的效用和運營效率。該地區的臨床檢查室經常進行跨境採購、合作研究和官民合作關係，以加速轉化研究和診斷檢驗。

在診斷領域採取策略性企業行動，結合研發領導地位、平台整合和合作夥伴關係，以加速臨床部署並實現商業性韌性。

DNA診斷領域的公司透過結合技術領先優勢、策略夥伴關係和服務導向經營模式來脫穎而出。產業領導企業正大力投資研發，以改善定序化學流程、提高檢測靈敏度並簡化從檢體到結果的工作流程。同時，軟體供應商和整合商正專注於雲端分析功能、與實驗室資訊系統的互通性以及合規的資料管治，以支援多站點部署和符合監管要求的報告。

為領導企業提供切實可行的策略建議，以加強其供應鏈、整合數位平台，並將臨床證據與商業化目標結合。

產業領導企業應採取務實的策略，在短期業務永續營運和長期創新之間取得平衡。首先，他們應優先考慮供應商多元化和靈活的採購條款，以保護其營運免受關稅波動和供應鏈中斷的影響。此外，針對高風險耗材和關鍵設備零件，必須對區域或本地製造能力進行針對性的投資。其次，他們應加快雲端服務、數據分析工具和測試資訊管理系統的整合，以縮短測試結果的獲取時間，提高品管，並實現可擴展的多站點運作。第三，他們應設計針對特定應用領域（例如帶因者篩檢、腫瘤檢測和傳染病檢查）的臨床證據項目，以滿足監管要求和支付者的期望。

一種透明且可重複的研究途徑，將與主要相關人員的對話與二手研究相結合，以檢驗對診斷技術的見解。

本調查方法結合了結構化的初步研究和針對性的二次分析，確保了研究結果的可靠性和可重複性。初步研究數據包括對實驗室經理、臨床遺傳學家、檢體採購經理和高級研發主管的詳細訪談，以了解營運限制、檢驗實踐和應用促進因素。除了這些定性調查外，還與儀器開發商和軟體供應商舉辦了研討會，以評估整合挑戰和不斷變化的產品藍圖。

一項決定性的整合，強調將技術創新、監管策略和商業性實施相結合，以實現永續的臨床影響。

總之，DNA診斷正處於一個轉捩點，需要技術能力、監管進步和商業策略的協調配合才能真正發揮臨床價值。優先考慮互通性、嚴格的臨床檢驗和適應性供應鏈策略的檢查室和產品開發商，將在提供可靠且具有臨床應用價值的結果方面超越同行。成熟的分子診斷技術與不斷擴展的定序應用之間的相互作用，為創新開闢了多元化的途徑，但成功的關鍵在於將技術進步轉化為檢驗且醫保覆蓋的臨床服務。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：DNA診斷市場：依技術分類

  • 螢光原位雜合反應
  • 微陣列
  • 聚合酵素鏈鎖反應
  • 定序
    • 次世代定序
    • 桑格定序

第9章：DNA診斷市場：依應用領域分類

  • 基因檢測
    • 攜帶者篩檢
    • 診斷測試
    • 新生兒篩檢
    • 預測性測試
  • 傳染病檢查
  • 腫瘤科檢查
  • 藥物基因體學
  • 產前檢查

第10章：DNA診斷市場：依產品類型分類

  • 消耗品
  • 裝置
  • 成套工具
  • 軟體和服務
    • 雲端服務
    • 數據分析工具
    • 檢查資訊管理系統

第11章 DNA診斷市場：依最終用戶分類

  • 診斷檢查室
  • 醫院和診所
  • 研究機構

第12章 DNA診斷市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 DNA診斷市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 DNA診斷市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國DNA診斷市場

第16章：中國DNA診斷市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Adaptive Biotechnologies
  • Agilent Technologies, Inc.
  • ARUP Laboratories
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • BioMerieux
  • Danaher Corporation
  • DNA Diagnostic A/S
  • Eurofins
  • Exact Sciences Corporation
  • F. Hoffmann-La Roche Ltd.
  • Hologic, Inc.
  • Illumina, Inc.
  • Invitae Corporation
  • Laboratory Corporation of America Holdings
  • Luminex Corporation
  • Myriad Genetics
  • Natera, Inc.
  • Oxford Nanopore Technologies PLC
  • Promega Corporation
  • QIAGEN GmbH
  • Quest Diagnostics
  • Siemens Healthineers
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.
  • Veracyte, Inc.
Product Code: MRR-4F7B2F382F2E

The DNA Diagnostics Market was valued at USD 13.59 billion in 2025 and is projected to grow to USD 14.77 billion in 2026, with a CAGR of 9.52%, reaching USD 25.70 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 13.59 billion
Estimated Year [2026] USD 14.77 billion
Forecast Year [2032] USD 25.70 billion
CAGR (%) 9.52%

A contemporary introduction to the DNA diagnostics ecosystem that frames scientific advances, regulatory shifts, and operational pressures reshaping diagnostic decisions

The introduction frames the contemporary DNA diagnostics landscape by highlighting the converging scientific, regulatory, and technological forces that are shaping diagnostic practice and research. Over recent years, advances in sequencing chemistry and bioinformatic pipelines have accelerated diagnostic throughput and precision, while regulatory agencies have evolved frameworks that emphasize analytical validity, clinical utility, and post-market surveillance. At the same time, laboratory workflows are adapting to balance high-complexity testing with pressures for faster turnaround times and cost containment.

This section positions stakeholders to understand how operational realities, including supply chain robustness and laboratory informatics, interact with clinical demand. It also outlines how patient expectations and payor scrutiny are prompting providers to justify diagnostic pathways with clearer evidence of clinical benefit. Taken together, these dynamics create both opportunities for innovation and imperatives for rigorous validation. As a result, leaders across diagnostics, healthcare delivery, and research must align technology investments, regulatory strategy, and clinical evidence generation to realize the promise of modern DNA-based testing.

How converging molecular technologies, expanded clinical applications, and integrated digital platforms are catalyzing systemic change across diagnostics and care pathways

Transformative shifts are underway across the DNA diagnostics ecosystem, driven by technological maturation and evolving clinical paradigms. Sequencing platforms, particularly next-generation sequencing alongside traditional Sanger approaches, now coexist with established molecular methods such as polymerase chain reaction, microarray technologies, and fluorescence in situ hybridization, enabling laboratories to select tools based on throughput, resolution, and clinical context. These technological choices influence downstream workflows, from sample preparation to data interpretation, and require parallel development of robust bioinformatics and quality-control processes.

Concurrently, applications have broadened to include complex areas like oncology testing and pharmacogenomics as well as classic clinical arenas such as genetic testing, prenatal testing, infectious disease testing, and newborn screening. Within genetic testing, subdomains such as carrier screening, diagnostic testing, newborn screening, and predictive testing each demand distinct validation and reporting standards. Product ecosystems have expanded to encompass consumables, instruments, kits, and increasingly sophisticated software and services, including cloud services, data analysis tools, and laboratory information management systems. This shift toward integrated solutions is reshaping vendor strategies and laboratory procurement decisions. Finally, end users ranging from diagnostic laboratories to hospitals and clinics and research institutes are recalibrating their capabilities to harness multi-modal testing, driving consolidation, strategic partnerships, and investments in workforce training and digital infrastructure.

Assessing the operational and strategic consequences of United States tariff adjustments in 2025 for supply chain resilience and procurement planning across diagnostics

The introduction of new tariff measures in the United States for 2025 adds a layer of complexity to global supply chains and procurement strategies in DNA diagnostics. Tariff changes alter the relative cost structure of imported instruments, reagents, and specialized consumables, which in turn affects decisions about sourcing, inventory buffers, and local manufacturing investments. Suppliers and laboratory operators must therefore reassess vendor contracts, evaluate alternative sourcing corridors, and consider the implications for long-term supplier relationships.

Beyond immediate cost pressures, tariffs can accelerate strategic choices such as reshoring certain manufacturing steps, qualifying additional regional suppliers, or negotiating for price adjustments and contractual protections. They also influence capital allocation decisions, as laboratories weigh the impact of higher import costs against the need to modernize instrumentation or expand sequencing capacity. In parallel, service providers and software vendors may face indirect effects through altered customer purchasing power and shifting priorities for capital expenditure. Consequently, organizations that proactively model tariff scenarios and engage in scenario planning will maintain operational resilience and preserve delivery commitments to clinicians and patients.

A nuanced segmentation analysis revealing how technologies, clinical applications, product offerings, and end-user needs collectively determine adoption trajectories and investment priorities

Key segmentation insights reveal how differentiated technology platforms, clinical applications, product portfolios, and end-user types are shaping adoption pathways and operational models. In terms of technology, legacy and targeted techniques such as fluorescence in situ hybridization and microarray continue to serve defined diagnostic niches while polymerase chain reaction retains dominance for rapid, high-sensitivity tests; sequencing modalities-encompassing both next-generation sequencing and Sanger sequencing-are expanding into comprehensive genomic profiling and confirmatory testing, respectively, with each approach bringing distinct throughput and informatics requirements.

Across applications, genetic testing remains multifaceted: carrier screening, diagnostic testing, newborn screening, and predictive testing each follow unique clinical and regulatory trajectories that influence laboratory validation and reporting. Infectious disease testing and prenatal testing demand rapid turnaround and robust quality controls, whereas oncology testing and pharmacogenomics rely increasingly on complex panels and iterative bioinformatic interpretation. Product type segmentation highlights the growing interdependence of consumables, instruments, kits, and software and services; cloud services, data analysis tools, and laboratory information management systems now play crucial roles in enabling scalable workflows and regulatory traceability. Finally, end users such as diagnostic laboratories, hospitals and clinics, and research institutes differ in scale, accreditation requirements, and resource allocations, shaping purchasing cycles and preferences for integrated solutions, managed services, or in-house development.

Comparative regional dynamics across the Americas, Europe Middle East & Africa, and Asia-Pacific that influence adoption, regulation, and supply strategies in diagnostics

Regional dynamics continue to exert strong influence on technology deployment, regulatory approaches, and collaborative ecosystems across the DNA diagnostics landscape. In the Americas, mature clinical networks and well-established reimbursement pathways support broad adoption of advanced genomic testing, yet cost pressures and evolving payer expectations necessitate clear evidence of utility and operational efficiency. Clinical laboratories in this region frequently engage in cross-border sourcing, collaborative research, and public-private partnerships that accelerate translational work and diagnostic validation.

In Europe, the Middle East & Africa, regulatory harmonization efforts and variable infrastructure capacities create a mosaic of opportunities and challenges; certain national health systems prioritize genomic medicine investments, while others emphasize decentralized diagnostics and capacity-building programs. Regional supply chain strategies and public procurement practices play significant roles in shaping adoption. In Asia-Pacific, rapid investment in sequencing capacity, growing diagnostic R&D hubs, and rising healthcare demand are driving technology uptake, with specific markets emphasizing local manufacturing and regulatory adaptation. Collectively, these regions present distinct strategic imperatives for manufacturers, laboratory networks, and service providers seeking to align product portfolios with regional clinical needs and regulatory frameworks.

Strategic corporate behaviors in diagnostics that combine R&D leadership, platform integration, and collaborative partnerships to accelerate clinical uptake and commercial resilience

Companies operating in DNA diagnostics are differentiating through a mix of technology leadership, strategic partnerships, and services-oriented business models. Industry leaders invest heavily in R&D to refine sequencing chemistries, enhance assay sensitivity, and streamline sample-to-result workflows. At the same time, software vendors and integrators are focusing on cloud-enabled analytics, interoperability with laboratory information systems, and compliance-ready data governance to support multi-site deployments and regulated reporting.

Across the competitive landscape, several trends merit attention: firms that combine instrument platforms with consumables and recurring-revenue kit offerings strengthen customer lock-in, while those that pursue modular, open-platform strategies appeal to laboratories seeking flexibility. Strategic collaborations between manufacturers and clinical networks accelerate real-world evidence generation and support payer engagement. Emerging companies often concentrate on niche clinical applications or disruptive assay formats, forcing incumbents to reconsider product roadmaps. Additionally, M&A activity and cross-sector partnerships-particularly those that pair diagnostics with digital health and therapeutic developers-are reshaping competitive boundaries and creating new channels for clinical adoption.

Actionable strategic recommendations for diagnostic leaders to fortify supply chains, integrate digital platforms, and align clinical evidence with commercialization objectives

Industry leaders should adopt pragmatic strategies that balance near-term operational resilience with long-term innovation. First, prioritize diversified sourcing and flexible procurement clauses to insulate operations from tariff volatility and supply chain disruptions. This should be complemented by targeted investments in local or regional manufacturing capabilities for high-risk consumables and critical instrument components. Second, accelerate integration of cloud services, data analysis tools, and laboratory information management systems to reduce turnaround times, improve quality control, and enable scalable multi-site operations. Third, design clinical evidence programs tailored to distinct application segments-such as carrier screening, oncology testing, and infectious disease testing-to satisfy both regulatory requirements and payer expectations.

Moreover, cultivate partnerships with hospitals, diagnostic laboratories, and research institutes to co-develop workflows and gather real-world performance data. Implement pricing and service models that reflect the total cost of ownership for customers, including support, software updates, and data management. Finally, invest in workforce development-upskilling laboratory personnel in bioinformatics and quality systems-to ensure that organizations can extract full value from advanced sequencing and integrated diagnostics platforms. Together, these steps will support sustainable growth while maintaining clinical credibility and operational agility.

A transparent, reproducible research approach that integrates primary stakeholder engagement and secondary evidence synthesis to validate diagnostic technology insights

The research methodology combines structured primary engagement with targeted secondary analysis to ensure robust, reproducible insights. Primary inputs included in-depth interviews with laboratory directors, clinical geneticists, procurement leaders, and senior R&D executives to capture operational constraints, validation practices, and adoption drivers. These qualitative engagements were complemented by workshops with instrument developers and software providers to assess integration challenges and evolving product roadmaps.

Secondary analysis synthesized regulatory guidance, peer-reviewed literature, and manufacturer technical documentation to validate technological capabilities and testing pathways. Data integrity was ensured through triangulation across multiple sources and through structured expert review panels that reconciled divergent viewpoints. Segmentation logic was applied consistently to map technologies-such as fluorescence in situ hybridization, microarray, polymerase chain reaction, and sequencing including next-generation sequencing and Sanger sequencing-to clinical applications and product types. Regional analysis incorporated policy trends, procurement practices, and infrastructure factors to contextualize deployment scenarios. Throughout, transparency and repeatability guided both data collection and analytic workflows.

A conclusive synthesis emphasizing the imperative to align technical innovation, regulatory strategy, and commercial execution to achieve durable clinical impact

In conclusion, DNA diagnostics stands at an inflection point where technical capability, regulatory evolution, and commercial strategy must align to realize clinical value. Laboratories and product developers that prioritize interoperability, rigorous clinical validation, and adaptive supply-chain strategies will outperform peers in delivering reliable, clinically actionable results. The interplay between established molecular methods and expanding sequencing applications creates diverse pathways for innovation, but success depends on translating technical advances into validated, reimbursable clinical services.

Looking ahead, resilient organizations will combine operational discipline with strategic partnerships, invest in digital infrastructure and workforce skills, and maintain proactive engagement with regulators and payers. By doing so, they will convert scientific progress into measurable improvements in patient care while sustaining competitive positioning in a rapidly evolving ecosystem. The momentum toward integrated diagnostics and data-driven decision-making offers clear opportunities for those who act deliberately and collaboratively.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. DNA Diagnostics Market, by Technology

  • 8.1. Fluorescence In Situ Hybridization
  • 8.2. Microarray
  • 8.3. Polymerase Chain Reaction
  • 8.4. Sequencing
    • 8.4.1. Next Generation Sequencing
    • 8.4.2. Sanger Sequencing

9. DNA Diagnostics Market, by Application

  • 9.1. Genetic Testing
    • 9.1.1. Carrier Screening
    • 9.1.2. Diagnostic Testing
    • 9.1.3. Newborn Screening
    • 9.1.4. Predictive Testing
  • 9.2. Infectious Disease Testing
  • 9.3. Oncology Testing
  • 9.4. Pharmacogenomics
  • 9.5. Prenatal Testing

10. DNA Diagnostics Market, by Product Type

  • 10.1. Consumables
  • 10.2. Instruments
  • 10.3. Kits
  • 10.4. Software And Services
    • 10.4.1. Cloud Services
    • 10.4.2. Data Analysis Tools
    • 10.4.3. Laboratory Information Management Systems

11. DNA Diagnostics Market, by End User

  • 11.1. Diagnostic Laboratories
  • 11.2. Hospitals And Clinics
  • 11.3. Research Institutes

12. DNA Diagnostics Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. DNA Diagnostics Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. DNA Diagnostics Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States DNA Diagnostics Market

16. China DNA Diagnostics Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Abbott Laboratories
  • 17.6. Adaptive Biotechnologies
  • 17.7. Agilent Technologies, Inc.
  • 17.8. ARUP Laboratories
  • 17.9. Becton, Dickinson and Company
  • 17.10. Bio-Rad Laboratories, Inc.
  • 17.11. BioMerieux
  • 17.12. Danaher Corporation
  • 17.13. DNA Diagnostic A/S
  • 17.14. Eurofins
  • 17.15. Exact Sciences Corporation
  • 17.16. F. Hoffmann-La Roche Ltd.
  • 17.17. Hologic, Inc.
  • 17.18. Illumina, Inc.
  • 17.19. Invitae Corporation
  • 17.20. Laboratory Corporation of America Holdings
  • 17.21. Luminex Corporation
  • 17.22. Myriad Genetics
  • 17.23. Natera, Inc.
  • 17.24. Oxford Nanopore Technologies PLC
  • 17.25. Promega Corporation
  • 17.26. QIAGEN GmbH
  • 17.27. Quest Diagnostics
  • 17.28. Siemens Healthineers
  • 17.29. Sysmex Corporation
  • 17.30. Thermo Fisher Scientific Inc.
  • 17.31. Veracyte, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL DNA DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL DNA DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL DNA DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES DNA DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA DNA DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL DNA DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY MICROARRAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY MICROARRAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY MICROARRAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY SANGER SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY SANGER SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY SANGER SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY CARRIER SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY CARRIER SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY CARRIER SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY NEWBORN SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY NEWBORN SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY NEWBORN SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY PREDICTIVE TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY PREDICTIVE TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY PREDICTIVE TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY ONCOLOGY TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY ONCOLOGY TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY ONCOLOGY TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY PHARMACOGENOMICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY PHARMACOGENOMICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY PHARMACOGENOMICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY PRENATAL TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY PRENATAL TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY PRENATAL TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY SOFTWARE AND SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY SOFTWARE AND SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY SOFTWARE AND SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY CLOUD SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY CLOUD SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY CLOUD SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY DATA ANALYSIS TOOLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY DATA ANALYSIS TOOLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY DATA ANALYSIS TOOLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY LABORATORY INFORMATION MANAGEMENT SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY LABORATORY INFORMATION MANAGEMENT SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY LABORATORY INFORMATION MANAGEMENT SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY HOSPITALS AND CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY HOSPITALS AND CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS DNA DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS DNA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS DNA DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS DNA DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS DNA DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS DNA DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS DNA DIAGNOSTICS MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS DNA DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA DNA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA DNA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA DNA DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA DNA DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA DNA DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA DNA DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA DNA DIAGNOSTICS MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA DNA DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA DNA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA DNA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA DNA DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA DNA DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA DNA DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA DNA DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA DNA DIAGNOSTICS MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA DNA DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA DNA DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA DNA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA DNA DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA DNA DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA DNA DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA DNA DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA DNA DIAGNOSTICS MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA DNA DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE DNA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE DNA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE DNA DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE DNA DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE DNA DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE DNA DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE DNA DIAGNOSTICS MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE DNA DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST DNA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST DNA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST DNA DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST DNA DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST DNA DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 130. MIDDLE EAST DNA DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST DNA DIAGNOSTICS MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST DNA DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 133. AFRICA DNA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. AFRICA DNA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 135. AFRICA DNA DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 136. AFRICA DNA DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 137. AFRICA DNA DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 138. AFRICA DNA DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. AFRICA DNA DIAGNOSTICS MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2032 (USD MILLION)
  • TABLE 140. AFRICA DNA DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC DNA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC DNA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC DNA DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC DNA DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC DNA DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC DNA DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC DNA DIAGNOSTICS MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2032 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC DNA DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 150. ASEAN DNA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. ASEAN DNA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 152. ASEAN DNA DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 153. ASEAN DNA DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 154. ASEAN DNA DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 155. ASEAN DNA DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. ASEAN DNA DIAGNOSTICS MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2032 (USD MILLION)
  • TABLE 157. ASEAN DNA DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. GCC DNA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. GCC DNA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 160. GCC DNA DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 161. GCC DNA DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 162. GCC DNA DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 163. GCC DNA DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. GCC DNA DIAGNOSTICS MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2032 (USD MILLION)
  • TABLE 165. GCC DNA DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPEAN UNION DNA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPEAN UNION DNA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPEAN UNION DNA DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPEAN UNION DNA DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPEAN UNION DNA DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPEAN UNION DNA DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPEAN UNION DNA DIAGNOSTICS MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPEAN UNION DNA DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 174. BRICS DNA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. BRICS DNA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 176. BRICS DNA DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 177. BRICS DNA DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 178. BRICS DNA DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 179. BRICS DNA DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. BRICS DNA DIAGNOSTICS MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2032 (USD MILLION)
  • TABLE 181. BRICS DNA DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 182. G7 DNA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 183. G7 DNA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 184. G7 DNA DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 185. G7 DNA DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 186. G7 DNA DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 187. G7 DNA DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. G7 DNA DIAGNOSTICS MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2032 (USD MILLION)
  • TABLE 189. G7 DNA DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 190. NATO DNA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 191. NATO DNA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 192. NATO DNA DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 193. NATO DNA DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 194. NATO DNA DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 195. NATO DNA DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. NATO DNA DIAGNOSTICS MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2032 (USD MILLION)
  • TABLE 197. NATO DNA DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 198. GLOBAL DNA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. UNITED STATES DNA DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 200. UNITED STATES DNA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 201. UNITED STATES DNA DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 202. UNITED STATES DNA DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 203. UNITED STATES DNA DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 204. UNITED STATES DNA DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 205. UNITED STATES DNA DIAGNOSTICS MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2032 (USD MILLION)
  • TABLE 206. UNITED STATES DNA DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 207. CHINA DNA DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 208. CHINA DNA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 209. CHINA DNA DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 210. CHINA DNA DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 211. CHINA DNA DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 212. CHINA DNA DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. CHINA DNA DIAGNOSTICS MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2032 (USD MILLION)
  • TABLE 214. CHINA DNA DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)